Assessments
Cancer
ADVERSE EVENT, CANCER
AEs were assessed from the first day of treatment through 30 days after the last dose (90 days for serious AEs) and were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Efficacy was assessed by the investigator using immune-related RECIST (irRECIST) (Bohnsack et al. 